Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,270 people get JAZZ articles and Market Currents by email alert.
Get email alerts on JAZZ »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
ISM Leads Market Down Bearish PathDavid Brown • Mon, Apr 1 -
-
Intermarket Trends Favor More Upside For StocksONeil Trader • Mon, Mar 11 -
-
-
-
-
-
4 Mid Caps Raking In Profits And Projected For GrowthZetaKap • Mon, Oct 1, 2012 -
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
Jazz Pharmaceuticals Still in TroubleEben Tessari • Thu, Jun 12, 2008
-
-
-
ISM Leads Market Down Bearish PathDavid Brown • Mon, Apr 1
-
-
Intermarket Trends Favor More Upside For StocksONeil Trader • Mon, Mar 11
-
-
-
-
4 Mid Caps Raking In Profits And Projected For GrowthZetaKap • Mon, Oct 1, 2012
-
-
-
-
-
-
-
-
-
3 Growth Mid Cap Stocks To ConsiderSupreme Alpha • Wed, Aug 22, 2012 -
-
-
Jazz Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptWed, May 5, 2010
-
Jazz Pharmaceuticals Inc. Q2 2008 Earnings Call TranscriptFri, Aug 8, 2008
-
Jazz Pharmaceuticals, Inc. Q1 2008 Earnings Call TranscriptTue, May 13, 2008
-
at CNBC.com (Apr 26, 2013)
-
at CNBC.com (Mar 19, 2013)
-
at MarketWatch.com (Mar 12, 2013)
-
at CNBC.com (Mar 5, 2013)
-
at MarketWatch.com (Oct 2, 2012)
-
at CNBC.com (Aug 15, 2012)
-
at CNBC.com (May 22, 2012)
-
at MarketWatch.com (Feb 7, 2012)
-
at MarketWatch.com (Jan 24, 2012)
-
at MarketWatch.com (Jan 6, 2012)
-
at MarketWatch.com (Jan 6, 2012)
-
PR Newswire (Jan 5, 2012)
-
PR Newswire (Dec 12, 2011)
-
at CNBC.com (Sep 21, 2011)
-
at CNBC.com (Sep 20, 2011)
-
at MarketWatch.com (Sep 20, 2011)
-
at MarketWatch.com (Sep 19, 2011)
-
at MarketWatch.com (Sep 8, 2011)
-
at MarketWatch.com (Sep 7, 2011)
JAZZ vs. ETF Alternatives
Company Description
We are a specialty pharmaceutical company that, since our inception, has focused on the development and commercialization of pharmaceutical products to meet important unmet medical needs in neurology and psychiatry. With our JZP-6 product candidate for the treatment of fibromyalgia, for which we... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, April 27, 2012, 1:37 PM Jefferies says Jazz Pharmaceuticals' (JAZZ +16.6%) acquisition of EUSA will add $0.76 to its FY13 earnings estimate and diversifies the company away from Xyrem. The firm now calls Jazz one of its top picks and raises its price target to $74. Comment! [Quick Ideas, M&A, On the Move]
- Thursday, April 26, 2012, 6:04 PM Jazz Pharmaceuticals (JAZZ) +11.2% AH after agreeing to acquire privately-held EUSA Pharma for as much as $700M in cash. EUSA's FDA-approved Erwinaze treatment blocks cell growth in patients with acute leukemia by cutting down asparagine levels in the bloodstream. Jazz expects the deal to add $210M-$230M in revenue and $0.75-$0.85/share in earnings. Comment! [Healthcare, M&A, On the Move]
- Wednesday, January 18, 2012, 8:44 AM After an agonizingly long halt for traders eager for a home run announcement, Jazz Pharmaceuticals (JAZZ) ends the suspense and merely confirms that it will combine with Azur Pharma to form a Dublin-based company. Shares are set to resume trading at 8:50 AM EST. Comment! [Healthcare, M&A]
- Monday, September 19, 2011, 4:29 PM Jazz Pharmaceuticals (JAZZ) is halted after the company announces it will merge with Ireland's Azur Pharma in an all-stock deal. Like Jazz, Azur develops drugs for treating women's health and central nervous system issues. The combined company will have $475M+ in revenue and $200M+ in cash flow in its first 12 months. 1 Comment [Healthcare, On the Move, M&A]
-
Capitalist Bull
Not much left to do, few setups remain. Patiently hold leading growth stocks through 1st pullbacks. http://stks.co/bV7p $ES_F $JAZZ $OCN - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 3 replies
-
-
-
- View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 3 replies
-
-
-
smokeyRose
What is up with $JAZZ ?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? - View all 2 replies
-
-
-
smokeyRose
Should i sell Should i sell My $JAZZ and $NPSP and Buy $SRPT ????? What to do What To Do What To Do - View all 2 replies
-
-
-
- View all 2 replies
-
tippycanoes: I bought under a dollar...sold at 6$... it haunts me. Literally could have retired -
-
- View all 14 replies
-
-
-
Michael Bryant
Jazz Pharmaceuticals (JAZZ) keeps rising. Could be good longterm holding. http://yhoo.it/yGLaZa;c= - View all 2 replies
-
-
-
- View all 5 replies
-
-
SlingWing9: They've all got lawsuits against them. All of them have legal depts, all allocate billions/yr for legal issues. Find one TBTF w/o lawsuits
-
- View all 1 replies
-
losbronces: And that is why people still play biotechs even though the odds of success are low.
-
- View all 3 replies
-
-
-
Michael Bryant
Not bad. Jazz Pharma (JAZZ) up 2%. Ulta Salon (ULTA) up 3.27%. Cabot Oil & Gas (COG) up 0.13%. http://seekingalpha.com/a/6rmy - View all 3 replies
-
-
-
- View all 1 replies
-
cowpieTX: i manage a diagnostic imaging center for a 17b market cap company. the cuts are real and they are deep. tread carefully.
-
Michael Bryant
Jazz Pharmaceuticals (JAZZ) is rising on unusual volume. It is a definite buy. PE ratio is very low. - View all 2 replies
-
-